ZeynepErogluMD

Physician

Overview of Dr. Eroglu

Dr. Zeynep Eroglu is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. She received her medical degree from David Geffen School of Medicine at UCLA and has been in practice 9 years. She is one of 168 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 49 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. She has more than 80 publications and over 500 citings.

Office
10920 McKinley Dr
Tampa, FL 33612
Book by Phone+1(440) 678-1143

Education & Training

Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 2012 - 2015
University of California (Irvine)Residency, Internal Medicine, 2008 - 2011
David Geffen School of Medicine at UCLAClass of 2008

Certifications & Licensure

CA State Medical License 2010 - 2025
FL State Medical License 2015 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Start of enrollment: 2016 Sep 07
Active, not recruiting
Phase 1
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma Start of enrollment: 2018 Jun 27
Active, not recruiting
Phase 1
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma Start of enrollment: 2018 Jun 14
Recruiting
Early Phase 1
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) Start of enrollment: 2019 Apr 01
Active, not recruiting
Phase 1
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases Start of enrollment: 2021 Jan 06
Recruiting
Phase 2
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients Start of enrollment: 2020 Dec 22
Active, not recruiting
Phase 2
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients Start of enrollment: 2020 Sep 24
Recruiting
Phase 2
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma Start of enrollment: 2021 May 24
Recruiting
Early Phase 1
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Start of enrollment: 2021 Oct 22
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma.
Ahmad A Tarhini, Zeynep Eroglu, Islam Eljilany, Jonathan S Zager, Ricardo J Gonzalez
Clinical Cancer Research. 2024-12-02
An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.
Zeynep Eroglu, Timothy Synold, Behnam Badie, An Liu, Arnab Chowdhury
Cancer Chemotherapy and Pharmacology. 2024-12-01
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma.
Tanya Ramadoss, Matthew Nichols, Christian Palacios, Zeynep Eroglu, Joseph Markowitz
Journal for Immunotherapy of Cancer. 2024-09-05

Journal Articles

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-cell Populations
Zeynep Eroglu, Iman Osman, Theodore S Nowicki, Antoni Ribas, Michael A Davies, Farbod Darvishian, Daniel Y Wang, Douglas B Johnson, Ravi K Amaravadi, Clinical Cancer Research

Lectures

Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (HSP90) inhibitor XL888 in advanced BRAFV600 mutant melanoma.
2019 ASCO Annual Meeting - 6/1/2019
Retrospective analysis of patients with sentinel lymph node (SLN) positive melanoma (MEL) who received adjuvant nivolumab (NIVO) without completion lymph node dissecti...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Desmoplastic Melanoma Highly Responsive to ImmunotherapyMay 11th, 2023
Desmoplastic Melanoma Responds to Pembrolizumb MonotherapyApril 20th, 2023
Woman's Breast Tumor Turned Out to Be Melanoma. But There Was Never a MoleMarch 13th, 2021
Join now to see all